B&K Corp eyes IPO to keep its slow-developing drugs alive
The company focuses on wound-healing PDGF drugs and its core product, Pro-101-2, isn’t expected to enter Phase 3 clinical trials for at least three more years Key Takeaways: B&K lost…
Recent Articles
RELATED ARTICLES
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK -
Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs
1672.HK
-
Akeso marks profit milestone with swift rights issue
9926.HK
- InSilico seeks IPO boost to get AI drugs over the line
-
CSPC Pharma taps R&D superstar in quest for new breakout drugs
1093.HK
